Neutralizing antibodies to interferon-beta and other immunological treatments for multiple sclerosis: prevalence and impact on outcomes (Q37488174)

20 August 2017

1 reference

title

Neutralizing antibodies to interferon-beta and other immunological treatments for multiple sclerosis: prevalence and impact on outcomes (English)

1 reference

20 August 2017

0 references

1 reference

Florian Deisenhammer

1

1 reference

PubMed ID

19453200

20 August 2017

language of work or name

1 reference

1 January 2009

1 reference

20 August 2017

1 reference

20 August 2017

23

1 reference

20 August 2017

5

1 reference

20 August 2017

379-396

1 reference

https://scigraph.springernature.com/pub.10.2165/00023210-200923050-00003

20 August 2017

0 references

cites work

Biological and clinical effects of interferon-beta ser at two doses

1 reference

https://api.crossref.org/works/10.2165%2F00023210-200923050-00003

Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00023210-200923050-00003

Neutralizing antibodies reduce the efficacy of betaIFN during treatment of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00023210-200923050-00003

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00023210-200923050-00003

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00023210-200923050-00003

Clinical-MRI correlations in a European trial of interferon beta-1b in secondary progressive MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00023210-200923050-00003

Serum IFN neutralizing antibodies and neopterin levels in a cross-section of MS patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00023210-200923050-00003

Neutralizing antibodies reduce MxA protein induction in interferon-beta-1a-treated MS patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00023210-200923050-00003

An Analysis of Neutralization Reaction of Interferon by Antibody: A Proposal on the Expression of Neutralization Titer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00023210-200923050-00003

Benefit of interferon beta-1a on MSFC progression in secondary progressive MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00023210-200923050-00003

Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00023210-200923050-00003

A comparative study of the relative bioavailability of different interferon beta preparations

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00023210-200923050-00003

Blocking effects of serum reactive antibodies induced by glatiramer acetate treatment in multiple sclerosis

21 January 2018

1 reference

12 December 2020

In vivo bioactivity of interferon-beta in multiple sclerosis patients with neutralising antibodies is titre-dependent

1 reference

12 December 2020

Magnetic resonance imaging as a surrogate outcome measure of disability in multiple sclerosis: have we been overly harsh in our assessment?

1 reference

12 December 2020

Randomized controlled trial of interferon-beta-1a in secondary progressive MS: MRI results

1 reference

12 December 2020

The evolution of neutralizing antibodies in multiple sclerosis patients treated with interferon beta-1b

1 reference

12 December 2020

Predictive markers for response to interferon therapy in patients with multiple sclerosis

1 reference

12 December 2020

MxA Gene Expression Analysis as an Interferon-β Bioactivity Measurement in Patients with Multiple Sclerosis and the Identification of Antibody-Mediated Decreased Bioactivity

1 reference

12 December 2020

Antibodies to glatiramer acetate do not interfere with its biological functions and therapeutic efficacy

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of recombinant human interferon-beta in healthy male volunteers

1 reference

12 December 2020

Evaluation of neutralizing antibodies in patients treated with recombinant interferon-beta ser

1 reference

12 December 2020

Interferon beta preparations for the treatment of multiple sclerosis patients differ in neutralizing antibody seroprevalence and immunogenicity

1 reference

12 December 2020

Disease-modifying therapy in multiple sclerosis: update and clinical implications

1 reference

12 December 2020

Appearance and disappearance of neutralizing antibodies during interferon-beta therapy

1 reference

12 December 2020

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

12 December 2020

Immunogenicity of interferon-beta in multiple sclerosis patients: influence of preparation, dosage, dose frequency, and route of administration. Danish Multiple Sclerosis Study Group.

1 reference

12 December 2020

Longitudinal MRI in multiple sclerosis: correlation between disability and lesion burden

1 reference

12 December 2020

1 reference

12 December 2020

Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group

1 reference

12 December 2020

Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosis

1 reference

12 December 2020

Interferon beta-1a in MS: results following development of neutralizing antibodies in PRISMS

1 reference

12 December 2020

Neutralizing antibodies during treatment of secondary progressive MS with interferon beta-1b

1 reference

12 December 2020

Persistent neutralizing antibodies abolish the interferon beta bioavailability in MS patients.

1 reference

12 December 2020

Immunogenicity of interferon beta: differences among products

1 reference

12 December 2020

Bioequivalence and the immunogenicity of biopharmaceuticals

1 reference

12 December 2020

Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group

1 reference

12 December 2020

Interferon-beta: the neutralizing antibody (NAb) titre predicts reversion to NAb negativity.

1 reference

12 December 2020

Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis

1 reference

12 December 2020

Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations

1 reference

12 December 2020

Fate of neutralizing and binding antibodies to IFN beta in MS patients treated with IFN beta for 6 years

1 reference

12 December 2020

Neutralizing antibodies against IFN-beta in multiple sclerosis: antagonization of IFN-beta mediated suppression of MMPs.

1 reference

12 December 2020

Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial

1 reference

12 December 2020

Neutralizing anti-interferon beta antibodies are associated with reduced side effects and delayed impact on efficacy of Interferon-beta

1 reference

12 December 2020

Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group

1 reference

12 December 2020

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

12 December 2020

Treatment with glatiramer acetate induces specific IgG4 antibodies in multiple sclerosis patients

1 reference

12 December 2020

The role of MRI as a surrogate outcome measure in multiple sclerosis

1 reference

12 December 2020

The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL.

1 reference

12 December 2020

Cellular responses to interferons and other cytokines: the JAK-STAT paradigm

1 reference

12 December 2020

Neutralizing antibodies to interferon beta-1a and interferon beta-1b in MS patients are cross-reactive

1 reference

12 December 2020

Relapses and progression of disability in multiple sclerosis

1 reference

12 December 2020

A randomized, double-blind, dose-comparison study of weekly interferon beta-1a in relapsing MS

1 reference

12 December 2020

Neutralizing antibodies during treatment of secondary progressive MS with interferon beta-1b

1 reference

12 December 2020

Epitope specificity of neutralizing antibodies against IFN-beta

1 reference

12 December 2020

Measurement of neutralizing antibodies to interferon beta in patients with multiple sclerosis.

1 reference

12 December 2020

Transcriptional regulation of interferon-stimulated genes

1 reference

12 December 2020

Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin

1 reference

12 December 2020

Clinical scoring methods for multiple sclerosis

1 reference

12 December 2020

Randomized controlled trial of interferon- beta-1a in secondary progressive MS: Clinical results

1 reference

12 December 2020

Pharmacodynamics of interferon beta in multiple sclerosis patients with or without serum neutralizing antibodies

1 reference

12 December 2020

Interferon-beta-1b slows progression of atrophy in RRMS: Three-year follow-up in NAb- and NAb+ patients.

1 reference

12 December 2020

Daily urinary neopterin excretion as an immunological marker of disease activity in multiple sclerosis

1 reference

12 December 2020

Prevalence of Multiple Sclerosis in Austria

1 reference

12 December 2020

Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study

1 reference

12 December 2020

The clinical impact of interferon beta antibodies in relapsing-remitting MS.

1 reference

12 December 2020

Immunogenicity and tolerability of an investigational formulation of interferon-β1a: 24- and 48-week interim analyses of a 2-year, single-arm, historically controlled, phase IIIb study in adults with multiple sclerosis

1 reference

12 December 2020

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

1 reference

12 December 2020

Synthesis in E. coli of a polypeptide with human leukocyte interferon activity

1 reference

12 December 2020

The natural history of relapses in multiple sclerosis

1 reference

12 December 2020

Interferon beta-1a in primary progressive multiple sclerosis

1 reference

12 December 2020

Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

1 reference

12 December 2020

Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS

1 reference

12 December 2020

Differing immunogenic potentials of interferon beta preparations in multiple sclerosis patients

1 reference

12 December 2020

Reduced effectiveness of long-term interferon-beta treatment on relapses in neutralizing antibody-positive multiple sclerosis patients: a Canadian multiple sclerosis clinic-based study

1 reference

12 December 2020

Interferon-β antibodies have a higher affinity in patients with neutralizing antibodies compared to patients with non-neutralizing antibodies

1 reference

12 December 2020

Multiplex analysis of expression of three IFNbeta-induced genes in antibody-positive MS patients

1 reference

12 December 2020

Phase I study of recombinant beta-interferon given by four-hour infusion.

1 reference

12 December 2020

Neutralizing antibodies hamper IFNbeta bioactivity and treatment effect on MRI in patients with MS.

1 reference

12 December 2020

Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis

1 reference

12 December 2020

A phase III trial of intramuscular recombinant interferon beta as treatment for exacerbating-remitting multiple sclerosis: design and conduct of study and baseline characteristics of patients. Multiple Sclerosis Collaborative Research Group (MSCRG).

1 reference

12 December 2020

Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-beta1a in relapsing-remitting multiple sclerosis. Prevention of Relapses and Disability by Interferon-beta1a Subcutaneously in

1 reference

12 December 2020

Immune surveillance in multiple sclerosis patients treated with natalizumab.

1 reference

12 December 2020

Assessment of different treatment failure criteria in a cohort of relapsing-remitting multiple sclerosis patients treated with interferon β: Implications for clinical trials

1 reference

12 December 2020

MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS.

1 reference

12 December 2020

Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN).

1 reference

12 December 2020

Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group

1 reference

12 December 2020

Biological markers of interferon-beta therapy: comparison among interferon-stimulated genes MxA, TRAIL and XAF-1.

1 reference

12 December 2020

Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study

1 reference

12 December 2020

The Multiple Sclerosis Functional Composite: a new clinical outcome measure for multiple sclerosis trials

1 reference

12 December 2020

Correlations between changes in disability and T2-weighted brain MRI activity in multiple sclerosis: a follow-up study

1 reference

12 December 2020

Dynamics of interferon-beta modulated mRNA biomarkers in multiple sclerosis patients with anti-interferon-beta neutralizing antibodies.

1 reference

12 December 2020

Mx proteins in blood leukocytes for monitoring interferon beta-1b therapy in patients with MS

1 reference

12 December 2020

Alternative and accessory pathways in the regulation of IFN-beta-mediated gene expression

1 reference

12 December 2020

Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

12 December 2020

Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis

1 reference

12 December 2020

10.2165/00023210-200923050-00003

Identifiers

DOI

1 reference

PubMed ID

19453200

Dimensions Publication ID

20 August 2017

0 references

1 reference

PubMed ID

19453200